Display options
Cite
Lee HY, Chung WJ, Jeon HK, et al. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study. Korean J Intern Med. 2016;31(2):277-87doi: 10.3904/kjim.2015.043.
Lee, H. Y., Chung, W. J., Jeon, H. K., Seo, H. S., Choi, D. J., Jeon, E. S., Kim, J. J., Shin, J. H., Kang, S. M., Lim, S. C., & Baek, S. H. (2016). Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study. The Korean journal of internal medicine, 31(2), 277-87. https://doi.org/10.3904/kjim.2015.043
Lee, Hae-Young, et al. "Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study." The Korean journal of internal medicine vol. 31,2 (2016): 277-87. doi: https://doi.org/10.3904/kjim.2015.043
Lee HY, Chung WJ, Jeon HK, Seo HS, Choi DJ, Jeon ES, Kim JJ, Shin JH, Kang SM, Lim SC, Baek SH. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study. Korean J Intern Med. 2016 Mar;31(2):277-87. doi: 10.3904/kjim.2015.043. Epub 2016 Feb 16. PMID: 26879662; PMCID: PMC4773723.
Copy Download .nbib Format: NLM
Share it on

Korean J Intern Med. 2016 Mar;31(2):277-87. doi: 10.3904/kjim.2015.043. Epub 2016 Feb 16.

Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.

The Korean journal of internal medicine

Hae-Young Lee, Wook-Jin Chung, Hui-Kyung Jeon, Hong-Seog Seo, Dong-Ju Choi, Eun-Seok Jeon, Jae-Joong Kim, Joon Han Shin, Seok-Min Kang, Sung Cil Lim, Sang-Hong Baek

Affiliations

  1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  2. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
  3. Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Korea.
  4. Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
  5. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  6. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  7. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  8. Department of Internal Medicine, Ajou University Hospital, Suwon, Korea.
  9. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  10. Department of Clinical Pharmacy, College of Pharmacy, The Catholic University of Korea, Seoul, Korea.
  11. Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

PMID: 26879662 PMCID: PMC4773723 DOI: 10.3904/kjim.2015.043

Abstract

BACKGROUND/AIMS: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF).

METHODS: One hundred patients with stable CHF (left ventricular ejection fraction [LVEF] < 45%) were enrolled. Enrolled patients started 1.25 mg bisoprolol treatment once daily, then up-titrated to the maximally tolerable dose, at which they were treated for 1 year.

RESULTS: Genotypic analysis was carried out, but the results were blinded to the investigators throughout the study period. At position 389 of the β-1 adrenergic receptor gene (ADRB1), the observed minor Gly allele frequency (Gly389Arg + Gly389Gly) was 0.21, and no deviation from Hardy-Weinberg equilibrium was observed in the genotypic distribution of Arg389Gly (p = 0.75). Heart rate was reduced from 80.8 ± 14.3 to 70.0 ± 15.0 beats per minute (p < 0.0001). There was no significant difference in final heart rate across genotypes. However, the Arg389Arg genotype group required significantly more bisoprolol compared to the Gly389X (Gly389Arg + Gly389Gly) group (5.26 ± 2.62 mg vs. 3.96 ± 2.05 mg, p = 0.022). There were no significant differences in LVEF changes or remodeling between two groups. Also, changes in exercise capacity and brain natriuretic peptide level were not significant. However, interestingly, there was a two-fold higher rate of readmission (21.2% vs. 10.0%, p = 0.162) and one CHF-related death in the Arg389Arg group.

CONCLUSIONS: The ADRB1 Gly389X genotype showed greater response to bisoprolol than the Arg389Arg genotype, suggesting the potential of individually tailoring β-blocker therapy according to genotype.

Keywords: Beta-blocker; Heart failure; Polymorphism; Receptors, adrenergic, beta

References

  1. Pharmacogenet Genomics. 2015 Nov;25(11):555-63 - PubMed
  2. Korean J Intern Med. 2014 Nov;29(6):754-63 - PubMed
  3. Circulation. 2000 Apr 11;101(14):1707-14 - PubMed
  4. Eur Heart J. 2000 Nov;21(22):1853-8 - PubMed
  5. N Engl J Med. 2002 Oct 10;347(15):1135-42 - PubMed
  6. Am Heart J. 2002 Nov;144(5):840-6 - PubMed
  7. Annu Rev Pharmacol Toxicol. 2003;43:381-411 - PubMed
  8. Eur J Heart Fail. 2003 Aug;5(4):463-8 - PubMed
  9. Am J Med. 2004 Oct 1;117(7):451-8 - PubMed
  10. Clin Pharmacokinet. 1991 May;20(5):350-73 - PubMed
  11. Clin Pharmacol Ther. 2005 Mar;77(3):127-37 - PubMed
  12. Pharmacogenet Genomics. 2005 Apr;15(4):227-34 - PubMed
  13. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5 - PubMed
  14. Clin Pharmacol Ther. 2006 Jul;80(1):23-32 - PubMed
  15. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288-93 - PubMed
  16. J Clin Invest. 2007 Jan;117(1):229-35 - PubMed
  17. Pharmacotherapy. 2007 Jun;27(6):874-87 - PubMed
  18. Clin Pharmacol Ther. 2007 Aug;82(2):215-8 - PubMed
  19. Pharmacol Ther. 2008 Jan;117(1):1-29 - PubMed
  20. Pharmacogenet Genomics. 2007 Nov;17(11):941-9 - PubMed
  21. Am J Cardiol. 2008 Sep 15;102(6):726-32 - PubMed
  22. J Cardiovasc Pharmacol. 2008 Nov;52(5):459-66 - PubMed
  23. Eur J Clin Pharmacol. 2009 Jan;65(1):3-17 - PubMed
  24. J Am Coll Cardiol. 2009 Jul 28;54(5):432-44 - PubMed
  25. Cardiovasc Drugs Ther. 2010 Feb;24(1):49-60 - PubMed
  26. Braz J Med Biol Res. 2010 Jun;43(6):565-71 - PubMed
  27. Br J Clin Pharmacol. 2011 Apr;71(4):556-65 - PubMed
  28. Circ Cardiovasc Genet. 2011 Dec;4(6):701-9 - PubMed
  29. Eur J Heart Fail. 2012 Jul;14(7):737-47 - PubMed
  30. PLoS One. 2012;7(7):e37659 - PubMed
  31. Circ J. 2012;76(8):2003-8 - PubMed
  32. PLoS One. 2012;7(10):e44324 - PubMed
  33. Eur J Heart Fail. 2013 Mar;15(3):258-66 - PubMed
  34. Mol Diagn Ther. 2013 Aug;17(4):205-19 - PubMed
  35. JACC Heart Fail. 2013 Feb;1(1):21-8 - PubMed
  36. JACC Heart Fail. 2013 Dec;1(6):488-96 - PubMed
  37. J Korean Med Sci. 2014 Apr;29(4):544-9 - PubMed
  38. Eur J Heart Fail. 2014 Jun;16(6):700-8 - PubMed
  39. Cardiovasc Res. 2000 Mar;45(4):889-99 - PubMed

Substances

MeSH terms

Publication Types